Research Topics
Species | Sherry X YangSummaryAffiliation: National Institutes of Health Country: USA Publications
| Collaborators
|
Detail Information
Publications
Epidermal growth factor receptor expression in breast cancerJeremy D Karlin
J Clin Oncol 23:8118-9; author reply 8119-20. 2005- PolyHEMA spheroids are an inadequate model for the drug resistance of the intractable solid tumorsKenneth Steadman
Medical Oncology Branch, National Cancer Institute, Bethesda, Maryland 20892, USA
Cell Cycle 7:818-29. 2008..We conclude that while spheroids (and confluent monolayer cells) show drug resistance, the mechanisms underlying this resistance diverge from those conferring resistance to intractable cancers... - Immunohistochemical detection of poly(ADP-ribose) polymerase inhibition by ABT-888 in patients with refractory solid tumors and lymphomasSherry X Yang
Division of Cancer Treatment and Diagnosis, Center for Cancer Research, National Cancer Institute, NIH, Bethesda, MD, USA
Cancer Biol Ther 8:2004-9. 2009..We aimed to determine whether the PARP inhibitor ABT-888 hits its therapeutic target in tumors by immunohistochemistry during a Phase 0 trial conducted at the National Cancer Institute... - Expression levels of eIF4E, VEGF, and cyclin D1, and correlation of eIF4E with VEGF and cyclin D1 in multi-tumor tissue microarraySherry X Yang
National Clinical Target Validation Laboratory, Division of Cancer Treatment and Diagnosis, Center for Cancer Research, National Cancer Institute, Bethesda, Maryland 20892, USA
Oncol Rep 17:281-7. 2007..20 and 0.31; all P>0.15). The significant association of eIF4E with VEGF and cyclin D1 in multiple tumors supports a role for eIF4E in translational regulation of proteins related to angiogenesis and growth... 
Akt phosphorylation at Ser473 predicts benefit of paclitaxel chemotherapy in node-positive breast cancerSherry X Yang
National Clinical Target Validation Laboratory, Division of Cancer Treatment and Diagnosis, National Cancer Institute, Bethesda, MD 20892, USA
J Clin Oncol 28:2974-81. 2010....- Circulating biomarkers of bevacizumab activity in patients with breast cancerNeelima Denduluri
Breast Cancer Section, Medical Oncology Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Heath, Bethesda, Maryland, USA
Cancer Biol Ther 7:15-20. 2008..Tumor samples were evaluated for VEGFR-2 mutations before and after bevacizumab... - Gene expression profile and angiogenic marker correlates with response to neoadjuvant bevacizumab followed by bevacizumab plus chemotherapy in breast cancerSherry X Yang
National Clinical Target Validation Laboratory, Division of Cancer Treatment and Diagnosis, Center for Cancer Research, National Cancer Institute, Bethesda, Maryland, USA
Clin Cancer Res 14:5893-9. 2008..To identify biomarkers and gene expression profile signatures to distinguish patients with partial response (PR) from those with stable disease (SD) and progressive disease (PD)... 
Cardiac toxicity and efficacy of trastuzumab combined with pertuzumab in patients with [corrected] human epidermal growth factor receptor 2-positive metastatic breast cancerChia C Portera
Medical Oncology Branch, National Cancer Institute, Bethesda, MD, USA
Clin Cancer Res 14:2710-6. 2008..To evaluate safety and efficacy of trastuzumab with pertuzumab in patients with human epidermal growth factor receptor 2 (HER2)-positive metastatic breast cancer who had progressive disease on trastuzumab-based therapy...- Phase II trial of ixabepilone, an epothilone B analog, in patients with metastatic breast cancer previously untreated with taxanesNeelima Denduluri
Breast Cancer Section, Medical Oncology Branch and Biostatistics, Office of the Clinical Director, Center for Cancer Research, National Clinical Target Validation Laboratory, Division of Cancer Treatment and Diagnosis, Bethesda, MD, USA
J Clin Oncol 25:3421-7. 2007..Ixabepilone was evaluated for efficacy and safety in a phase II clinical trial for women with metastatic breast cancer... - Designing phase 0 cancer clinical trialsAnthony J Murgo
Division of Cancer Treatment and Diagnosis and Center for Cancer Research, National Cancer Institute, Bethesda, Maryland 20892 2440, USA
Clin Cancer Res 14:3675-82. 2008.... - Poly(ADP-ribose) polymerase inhibition enhances p53-dependent and -independent DNA damage responses induced by DNA damaging agentDiana Nguyen
Division of Cancer Treatment and Diagnosis, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA
Cell Cycle 10:4074-82. 2011..Abrogating the cell-cycle arrest induced by PARP inhibition plus chemotherapeutics may be a strategy in the treatment of BRCA-proficient cancer... - Antiangiogenic and antitumor effects of bevacizumab in patients with inflammatory and locally advanced breast cancerSuparna Bonthala Wedam
Cancer Therapeutics Branch, Center for Cancer Research, National Cancer Institute, 8901 Wisconsin Avenue, Building 8, Rm 5101, Bethesda, MD 20889-5015, USA
J Clin Oncol 24:769-77. 2006..3% in extravascular-extracellular volume fraction (P = .002) were seen after bevacizumab alone. CONCLUSION: Bevacizumab has inhibitory effects on VEGF receptor activation and vascular permeability, and induces apoptosis in tumor cells... - p53, HER2 and tumor cell apoptosis correlate with clinical outcome after neoadjuvant bevacizumab plus chemotherapy in breast cancerSherry X Yang
National Clinical Target Validation Laboratory, Division of Cancer Treatment and Diagnosis, National Cancer Institute, National Institutes of Health, Bldg 37 Rm 1048, Bethesda, MD 20892, USA
Int J Oncol 38:1445-52. 2011..Our data suggest that baseline p53, apoptosis and HER2 are each significantly associated with outcome in patients who received bevacizumab plus chemotherapy... - Bevacizumab and breast cancer: current therapeutic progress and future perspectivesSherry X Yang
National Clinical Target Validation Laboratory, Division of Cancer Treatment and Diagnosis, National Cancer Institute, NIH, Building, 37 Room 1048, 37 Convent Drive, Bethesda, MD 20892 USA
Expert Rev Anticancer Ther 9:1715-25. 2009..The biomarkers of benefit will ultimately help identify the subgroups of patients who specifically benefit from anti-VEGF therapy with bevacizumab... - A pilot study to evaluate the vascular endothelial growth factor receptor tyrosine kinase inhibitor AZD2171 and chemotherapy in locally advanced and inflammatory breast cancerNeelima Denduluri
Breast Cancer Section, Medical Oncology Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA
Clin Breast Cancer 6:460-3. 2005 - Functional activity and tumor-specific expression of dual oxidase 2 in pancreatic cancer cells and human malignancies characterized with a novel monoclonal antibodyYonghzong Wu
Laboratory of Molecular Pharmacology, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892, USA
Int J Oncol 42:1229-38. 2013.... - Gene expression patterns and profile changes pre- and post-erlotinib treatment in patients with metastatic breast cancerSherry X Yang
Cancer Therapeutics Branch in Center for Cancer Research, National Cancer Institute, NIH, Bethesda, Maryland 20889, USA
Clin Cancer Res 11:6226-32. 2005.... - Phase I clinical trial of oral 2-methoxyestradiol, an antiangiogenic and apoptotic agent, in patients with solid tumorsWilliam L Dahut
Medical Oncology Clinical Research Unit, Center for Cancer Research, National Cancer Institute, Bethesda, Maryland 20892, USA
Cancer Biol Ther 5:22-7. 2006..2ME2 treatment had no effect on microvessel density (CD31 immunostaining) and cell proliferation (Ki-67 immunostaining). A new formulation of 2ME2 with improved bioavailability is currently being developed... - Phase 0 clinical trials: conceptions and misconceptionsShivaani Kummar
Center for Cancer Research, Division of Cancer Treatment and Diagnosis, National Cancer Institute, Bethesda, Maryland 20892, USA
Cancer J 14:133-7. 2008..We review here the fundamental requirements of clinical studies conducted under an exploratory IND and address some common misconceptions regarding oncologic phase 0 trials... - Phase II clinical trial of ixabepilone (BMS-247550), an epothilone B analog, in metastatic and locally advanced breast cancerJennifer A Low
Cancer Therapeutics Branch, Center for Cancer Research, National Cancer Institute, Bethesda, MD 20889-5015, USA
J Clin Oncol 23:2726-34. 2005..Sensory neuropathy was mild with grade 3 neurotoxicity rarely seen. Microtubule stabilization occurred in tumor biopsies after treatment with ixabepilone... - Multiplexed cell signaling analysis of human breast cancer applications for personalized therapyJulia D Wulfkuhle
Center for Applied Proteomics and Molecular Medicine, George Mason University, Manassas, Virginia 20110, USA
J Proteome Res 7:1508-17. 2008..Analysis of biopsy material from clinical trials for targeted therapeutics demonstrates the feasibility and utility of comprehensive signal pathway activation profiling for molecular analysis...